Fibrinolytic Agents

Name
Fibrinolytic Agents
Accession Number
DBCAT000013
Description

Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Some drugs in this category may have indirect fibrinolytic/thrombolytic effects.

Drugs
DrugDrug Description
AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
AncrodAn anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
Apadamtase alfaA recombinant human ADAMTS13 for enzyme replacement therapy in patients with congenital thrombotic thrombocytopenic purpura.
ApafantApafant is a small molecule drug. The usage of the INN stem '-pafant' in the name indicates that Apafant is a platelet-activating factor antagonist. Apafant has a monoisotopic molecular weight...
AstaxanthinInvestigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma.
BenzaroneBenzarone is a small molecule drug. Benzarone has a monoisotopic molecular weight of 266.09 Da.
BrinaseNot Annotated
Cinnamic acidNot Annotated
DefibrotideA mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
Dermatan sulfateA medication indicated to prevent deep vein thrombosis.
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DicoumarolFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
IsbogrelIsbogrel is a small molecule drug. Isbogrel has a monoisotopic molecular weight of 281.14 Da.
LimaprostAn oral prostaglandin E1 analogue used to improve symptoms associated with thromboangiitis obliterans, acquired lumbar spinal canal stenosis, and other ischemic conditions.
LinotrobanLinotroban is a small molecule drug. Linotroban has a monoisotopic molecular weight of 341.04 Da.
MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
PamiteplaseNot Annotated
PlasminogenPlasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia).
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
SaruplaseNot Annotated
StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
SulodexideA drug used to treat chronic venous ulcers in the legs.
SulotrobanSulotroban is a small molecule drug. Sulotroban has a monoisotopic molecular weight of 335.08 Da.
TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction, pulmonary emboli, and ischemic stroke.
UrokinaseA low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
VapiprostVapiprost is a small molecule drug. Vapiprost has a monoisotopic molecular weight of 477.29 Da.